Brought to you by 
BMS adds to cancer pipeline in $235mm Kosan takeover
04 Aug 2008
Executive Summary
Bristol-Myers Squibb agreed to buy publicly traded Kosan Biosciences for $235mm (or $190mm after deducting Kosan's projected net cash balance on June 30, 2008), paying $5.50 cash (a 227% premium) for each of the oncology biotech's 42.65mm shares outstanding.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS adds to cancer pipeline in $235mm Kosan takeover
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice